← Back to Search

111In-DAC Imaging Agent for Lung and Brain Cancer

Phase 1

Waitlist Available

Research Sponsored by Copharos

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have an ECOG performance status of Zero or One

Are being evaluated for known or suspected non-small-cell lung cancer (NSCLC), or known brain lesions consistent with metastatic lung cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is investigating the safety and efficacy of a new imaging agent for brain and lung cancer.

Who is the study for?

This trial is for adults over 18 with lung cancer or brain tumors linked to lung cancer, who haven't had treatment yet. They must be scheduled for a biopsy or have a recent diagnosis and agree to use birth control. People with severe allergies, unstable health conditions, kidney or liver issues, or those on certain medications can't join.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of a new imaging agent called 111In-DAC in detecting lung and brain cancers using planar and SPECT imaging techniques. It aims to improve how we see these cancers inside the body.See study design

What are the potential side effects?

Potential side effects may include allergic reactions to components of the imaging agent. Since it's used for scanning purposes, other risks might be related to exposure to radiation during image capture.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am fully active or can carry out light work.

Select...

I am being checked for lung cancer or brain lesions from lung cancer.

Select...

I have brain symptoms from lung cancer and haven't had brain radiation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

CopharosLead Sponsor

1 Previous Clinical Trials

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00040560 — Phase 1

Lung Cancer Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00040560 — Phase 1

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00040560 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do seniors aged 75 or older qualify for this investigation?

"This clinical trial only permits individuals aged 18 to 65. There are 407 trials that admit minors, while 4577 studies accept seniors as participants."

Answered by AI